PDF(Pubmed)
Abstract：
UNASSIGNED: Rupture and bleeding from Gastroesophageal Varices (GEVs) are major complications among patients with chronic liver disease (CLD) and are associated with a high mortality rate. Hence, identifying factors of Gastroesophageal Variceal Hemorrhage (GEVH) is essential for the management and prevention of this fatal outcome.
UNASSIGNED: To assess the prevalence of GEVH and its associated factors among patients with CLD in Northwest Ethiopia.
UNASSIGNED: An institutional based cross-sectional study design was employed on a total of 262 patients. The data was entered into Epi-Data version 3.1, and then exported and analyzed using STATA version 14. The distribution of variables was checked using kolmogorov-smirnov test. Bivariable logistic regression model was fitted to select variables for multivariable analysis. In the final model, adjusted odds ratio with 95% confidence level and P-value less than 0.05 were used to assess degree of association.
UNASSIGNED: The mean age of the study subjects was found to be 37.76 years (SD ± 11.62). The prevalence of GEVH was found to be 52% (95% CI: 49.6-54.2). Patients with grade F2 and F3 varices have 3.41 times (AOR: 3.41, 95% CI: 2.33-4.74) and 3.33 times (AOR: 3.33, 95% CI: 2.55-4.12) higher odds of bleeding, respectively. Patients not taking beta blocker have 2.38 times (AOR: 2.38, 95% CI: 1.82-3.90) increased odds of bleeding. Patients with more than three years of duration of illness have 2 times (AOR: 2.19, 95% CI: 1.39-3.99) increased odds of bleeding. Patients with platelet number less than 50,000/μl have 3.46 times (AOR: 3.46, 95% CI: 2.55-4.17) higher odds of bleeding.
UNASSIGNED: GEVH is found to be high in patients with CLD seen at university of Gondar Hospital. Higher grade of varices, non-use of beta blockers, presence of infection, platelet number and age are associated with higher occurrence of bleeding, pointing the possibility of averting this fatal complication, for most of the identified factors are preventable.
UNASSIGNED: To assess the prevalence of GEVH and its associated factors among patients with CLD in Northwest Ethiopia.
UNASSIGNED: An institutional based cross-sectional study design was employed on a total of 262 patients. The data was entered into Epi-Data version 3.1, and then exported and analyzed using STATA version 14. The distribution of variables was checked using kolmogorov-smirnov test. Bivariable logistic regression model was fitted to select variables for multivariable analysis. In the final model, adjusted odds ratio with 95% confidence level and P-value less than 0.05 were used to assess degree of association.
UNASSIGNED: The mean age of the study subjects was found to be 37.76 years (SD ± 11.62). The prevalence of GEVH was found to be 52% (95% CI: 49.6-54.2). Patients with grade F2 and F3 varices have 3.41 times (AOR: 3.41, 95% CI: 2.33-4.74) and 3.33 times (AOR: 3.33, 95% CI: 2.55-4.12) higher odds of bleeding, respectively. Patients not taking beta blocker have 2.38 times (AOR: 2.38, 95% CI: 1.82-3.90) increased odds of bleeding. Patients with more than three years of duration of illness have 2 times (AOR: 2.19, 95% CI: 1.39-3.99) increased odds of bleeding. Patients with platelet number less than 50,000/μl have 3.46 times (AOR: 3.46, 95% CI: 2.55-4.17) higher odds of bleeding.
UNASSIGNED: GEVH is found to be high in patients with CLD seen at university of Gondar Hospital. Higher grade of varices, non-use of beta blockers, presence of infection, platelet number and age are associated with higher occurrence of bleeding, pointing the possibility of averting this fatal complication, for most of the identified factors are preventable.
摘要：
■胃食管静脉曲张破裂出血是慢性肝病（CLD）患者的主要并发症，并与高死亡率相关。因此，确定胃食管静脉曲张出血（GEVH）的因素对于治疗和预防这种致命结局至关重要。
■评估埃塞俄比亚西北部CLD患者中GEVH的患病率及其相关因素。
■对总共262名患者进行了基于机构的横断面研究设计。将数据输入Epi-Data版本3.1，然后使用STATA版本14进行导出和分析。使用kolmogorov-smirnov检验检查变量的分布。拟合双变量逻辑回归模型以选择变量进行多变量分析。在最终模型中，使用95%置信水平和P值小于0.05的校正比值比评估关联程度.
■研究对象的平均年龄为37.76岁(SD±11.62)。发现GEVH的患病率为52％（95％CI：49.6-54.2）。F2和F3级静脉曲张患者的出血几率高3.41倍（AOR：3.41，95％CI：2.33-4.74）和3.33倍（AOR：3.33，95％CI：2.55-4.12），分别。未服用β受体阻滞剂的患者出血几率增加2.38倍（AOR：2.38，95％CI：1.82-3.90）。病程超过3年的患者出血几率增加2倍(AOR:2.19,95%CI:1.39-3.99)。血小板数量小于50,000/μl的患者出血几率高3.46倍（AOR：3.46，95％CI：2.55-4.17）。
■在冈达大学医院看到的CLD患者中，发现GEVH高。静脉曲张等级较高，不使用β受体阻滞剂，感染的存在，血小板数量和年龄与较高的出血发生率有关，指出避免这种致命并发症的可能性，因为大多数确定的因素是可以预防的。
■评估埃塞俄比亚西北部CLD患者中GEVH的患病率及其相关因素。
■对总共262名患者进行了基于机构的横断面研究设计。将数据输入Epi-Data版本3.1，然后使用STATA版本14进行导出和分析。使用kolmogorov-smirnov检验检查变量的分布。拟合双变量逻辑回归模型以选择变量进行多变量分析。在最终模型中，使用95%置信水平和P值小于0.05的校正比值比评估关联程度.
■研究对象的平均年龄为37.76岁(SD±11.62)。发现GEVH的患病率为52％（95％CI：49.6-54.2）。F2和F3级静脉曲张患者的出血几率高3.41倍（AOR：3.41，95％CI：2.33-4.74）和3.33倍（AOR：3.33，95％CI：2.55-4.12），分别。未服用β受体阻滞剂的患者出血几率增加2.38倍（AOR：2.38，95％CI：1.82-3.90）。病程超过3年的患者出血几率增加2倍(AOR:2.19,95%CI:1.39-3.99)。血小板数量小于50,000/μl的患者出血几率高3.46倍（AOR：3.46，95％CI：2.55-4.17）。
■在冈达大学医院看到的CLD患者中，发现GEVH高。静脉曲张等级较高，不使用β受体阻滞剂，感染的存在，血小板数量和年龄与较高的出血发生率有关，指出避免这种致命并发症的可能性，因为大多数确定的因素是可以预防的。
